NHL Peripheral T-cell lymphoma (PTCL) Market Spotlight Report 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: NHL: Peripheral T-cell lymphoma (PTCL)” report has been added to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the Peripheral T-Cell Lymphoma (PTCL) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• The publisher estimates that in 2017, there were approximately 19,950 incident cases of peripheral T-cell lymphoma (PTCL) worldwide, and forecasts that number to increase to 23,880 incident cases by 2026.
• It is estimated that the majority of diagnosed cases were in males in 2017.
• The incidence of PTCL is highest among older individuals aged 60+ years. The approved drugs in the PTCL space focus on a wide variety of targets. These drugs are administered via the intravenous and oral routes.
• The majority of industry-sponsored drugs in active clinical development for PTCL are in Phase II. Therapies in development for PTCL focus on a wide variety of targets. These therapies are administered via the oral and intravenous routes.
• High-impact upcoming events for drugs in the PTCL space comprise topline Phase II trial results for IPH4102 and an expected supplemental CHMP opinion for Adcetris.
• The overall likelihood of approval of a Phase I hematologic asset is 8.6%, and the average probability a drug advances from Phase III is 59.1%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
• The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for PTCL have been in the early and mid-phases of development, with 93% of trials in Phase I-II, and only 7% in Phase III-IV.
• The US has a substantial lead in the number of PTCL clinical trials globally. France and the UK lead the major European markets, while China has the top spot in Asia.
• Clinical trial activity in the PTCL space is dominated by completed trials. Bristol Myers Squibb has the highest number of completed clinical trials for PTCL, with 11 trials.
• Bristol Myers Squibb leads industry sponsors with the highest overall number of clinical trials for PTCL, followed by Seagen and Takeda.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

• Subtypes

TREATMENT

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

• ALXN2075 for PTCL (December 8, 2019)
• Tipifarnib (Oncology) for PTCL (December 8, 2019)
• Copiktra for PTCL (December 7, 2019)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

• Curon Picks Up China-Plus Rights to Rhizen’s Tenalisib

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

• Sponsors by status
• Sponsors by phase

BIBLIOGRAPHY

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/rozir

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900